Search company, investor...

Poniard Pharmaceuticals

poniard.com

Founded Year

1984

Stage

PIPE - III | IPO

Total Raised

$15.75M

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration resistant prostate cancers (also known as hormone refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

Headquarters Location

7000 Shoreline Court Suite 270

South San Francisco, California, 94080,

United States

650-583-3774

Missing: Poniard Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Poniard Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Poniard Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Poniard Pharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Poniard Pharmaceuticals Patents

Poniard Pharmaceuticals has filed 10 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/6/2009

5/15/2012

Experimental cancer drugs, Monoclonal antibodies, Antineoplastic drugs, Monoclonal antibodies for tumors, Fluoroarenes

Grant

Application Date

2/6/2009

Grant Date

5/15/2012

Title

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Antineoplastic drugs, Monoclonal antibodies for tumors, Fluoroarenes

Status

Grant

Latest Poniard Pharmaceuticals News

Poniard Pharmaceuticals Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Dec 3, 2016

Poniard Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 09:19 EST 3 Dec 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Poniard Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Poniard Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Poniard Pharmaceuticals, Inc. since January 2007. Key Findings Provides intelligence on Poniard Pharmaceuticals, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Poniard Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Poniard Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Poniard Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Poniard Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Poniard Pharmaceuticals founded?

    Poniard Pharmaceuticals was founded in 1984.

  • Where is Poniard Pharmaceuticals's headquarters?

    Poniard Pharmaceuticals's headquarters is located at 7000 Shoreline Court, South San Francisco.

  • What is Poniard Pharmaceuticals's latest funding round?

    Poniard Pharmaceuticals's latest funding round is PIPE - III.

  • How much did Poniard Pharmaceuticals raise?

    Poniard Pharmaceuticals raised a total of $15.75M.

  • Who are the investors of Poniard Pharmaceuticals?

    Investors of Poniard Pharmaceuticals include Highbridge Capital Management, TD Capital, TD Asset Management, T. Rowe Price, MPM Capital and 24 more.

  • Who are Poniard Pharmaceuticals's competitors?

    Competitors of Poniard Pharmaceuticals include Orexigen Therapeutics, Threshold Pharmaceuticals, Pique Therapeutics, ARIAD Pharmaceuticals, XenoPort, Jennerex Biotherapeutics, Onyx Pharmaceuticals, Talon Therapeutics, Crux Biomedical, Allos Therapeutics and 19 more.

Compare Poniard Pharmaceuticals to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

P
Pique Therapeutics

Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.

Immunservice Logo
Immunservice

Immunservice is a biopharmaceutical company addressing orphan disease indications as well as large market indication areas, especially those of high unmet medical need.Immunservice's biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.Biomimetic therapy has the clear potential to cure patients with cancer, even those who are in urgent need and have little or no treatment alternatives.

I
InCode BioPharmaceutics

Incode BioPharmaceutics, Inc., has developed a product candidate, HC3-1496, that specifically targets the complement pathway. The mechanism-of-action of HC3-1496 results in enzymatic depletion of the complement protein C3, the key component for all three pathways of complement activation (alternative, classical, and mannose-lectin). The company's preclinical results show rapid depletion of C3 without any observed adverse events, including in primates. Importantly, HC3-1496 depletes C3 without the downstream activation of C5, thus preventing the formation of the C5a anaphylatoxin. A recent exciting result is the demonstration that HC3-1496 enhances the efficacy of an anti-CD20 mAb in a murine cancer model. These data will be presented at the upcoming American Society of Hematology (ASH) meeting in December. This clinical avenue is a high priority for InCode, and also underscores the increased appreciation for the role of complement in certain oncologic settings. The company have also demonstrated efficacy in several other animal models of human disease, including collagen-induced arthritis (RA), myocardial ischemia/reperfusion, and age related macular degeneration (AMD). The company have also demonstrated that HC3-1496 prevents the lysis of erythrocytes in patients with paroxysmal nocturnal hemoglobinuria (PNH). Given the emerging role of complement activation in the pathogenesis of grievous human disease, Incode intends to exploit the potent activity of HC3-1496. The company intend to initiate human clinical trials in selected indications within 18 months.

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

C
Can-Fite Biopharma

Can-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.